NO20181511A1 - Survivin-avledede peptider og bruken av dem - Google Patents
Survivin-avledede peptider og bruken av demInfo
- Publication number
- NO20181511A1 NO20181511A1 NO20181511A NO20181511A NO20181511A1 NO 20181511 A1 NO20181511 A1 NO 20181511A1 NO 20181511 A NO20181511 A NO 20181511A NO 20181511 A NO20181511 A NO 20181511A NO 20181511 A1 NO20181511 A1 NO 20181511A1
- Authority
- NO
- Norway
- Prior art keywords
- survivin
- derived peptides
- tumor
- cells
- peptides
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 102000043129 MHC class I family Human genes 0.000 abstract 1
- 108091054437 MHC class I family Proteins 0.000 abstract 1
- 102000000763 Survivin Human genes 0.000 abstract 1
- 108010002687 Survivin Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 238000011065 in-situ storage Methods 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464448—Regulators of development
- A61K39/46445—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/49—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
MHC klasse I-restrikte peptider avledet fra det tumor-assosierte antigenet, survivin, der peptidene er i stand til å binde klasse I HLA-molekyler med en høy affinitet, er i stand til å utløse INF-γ-produserende celler i en PBL-populasjon til en kreftpasient og er i stand til in situ deteksjon av cytotoksiske T-celler i et tumor vev, terapeutiske og diagnostiske blandinger som omfatter peptidet og anvendelserderav.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/354,090 US20040210035A1 (en) | 2002-01-30 | 2003-01-30 | Survivin-derived peptides and use thereof |
US10/715,417 US7892559B2 (en) | 2002-01-30 | 2003-11-19 | Survivin-derived peptides and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20181511A1 true NO20181511A1 (no) | 2004-08-02 |
NO344833B1 NO344833B1 (no) | 2020-05-18 |
Family
ID=46241465
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20170133A NO343244B1 (no) | 2003-01-30 | 2017-01-27 | Survivin-avledede peptider og bruken av dem |
NO20181511A NO344833B1 (no) | 2003-01-30 | 2018-11-23 | Survivin-avledede peptider og bruken av dem |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20170133A NO343244B1 (no) | 2003-01-30 | 2017-01-27 | Survivin-avledede peptider og bruken av dem |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP2857035B1 (no) |
JP (3) | JP5509185B2 (no) |
CN (1) | CN103288920B (no) |
DK (1) | DK2359841T3 (no) |
ES (3) | ES2633389T3 (no) |
HK (3) | HK1134030A1 (no) |
NO (2) | NO343244B1 (no) |
PT (1) | PT2359841E (no) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201604755D0 (en) * | 2016-03-21 | 2016-05-04 | Vaxeal Res Sas | Immunogenic compositions |
JPWO2021024742A1 (no) * | 2019-08-06 | 2021-02-11 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5342774A (en) | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
EP0658113B1 (en) | 1992-08-31 | 2004-10-20 | Ludwig Institute For Cancer Research | Isolated nonapeptide derived from mage-3 gene and presented by hla-a1, and uses thereof |
US6096313A (en) | 1996-02-09 | 2000-08-01 | Ludwig Institute For Cancer Research | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
DE69739105D1 (de) | 1996-11-20 | 2008-12-24 | Univ Yale | Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation |
WO1999050440A2 (en) * | 1998-04-01 | 1999-10-07 | Yale University | Method to identify modulators of survivin - tubulin interaction |
AU4990999A (en) * | 1998-07-14 | 2000-02-07 | Jenner Biotherapies, Inc. | Survivin, and peptides thereof, as an anti-cancer vaccine |
DE10225144A1 (de) * | 2002-05-29 | 2003-12-18 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
PL2087904T3 (pl) * | 2003-11-19 | 2014-01-31 | Survac Aps | Zastosowanie terapeutyczne peptydów pochodzących z białek BcL-XL u pacjentów z rakiem |
-
2004
- 2004-01-30 ES ES14191676.7T patent/ES2633389T3/es not_active Expired - Lifetime
- 2004-01-30 PT PT101808780T patent/PT2359841E/pt unknown
- 2004-01-30 ES ES14191677.5T patent/ES2661082T3/es not_active Expired - Lifetime
- 2004-01-30 DK DK10180878.0T patent/DK2359841T3/en active
- 2004-01-30 EP EP14191677.5A patent/EP2857035B1/en not_active Expired - Lifetime
- 2004-01-30 ES ES10180878.0T patent/ES2529203T3/es not_active Expired - Lifetime
- 2004-01-30 CN CN201310159752.8A patent/CN103288920B/zh not_active Expired - Lifetime
-
2009
- 2009-06-22 HK HK10101403.7A patent/HK1134030A1/xx not_active IP Right Cessation
-
2011
- 2011-12-09 JP JP2011270382A patent/JP5509185B2/ja not_active Expired - Lifetime
-
2012
- 2012-05-23 JP JP2012117831A patent/JP5931585B2/ja not_active Expired - Lifetime
-
2015
- 2015-01-23 JP JP2015011806A patent/JP6021961B2/ja not_active Expired - Lifetime
- 2015-10-07 HK HK15109796.0A patent/HK1209050A1/xx not_active IP Right Cessation
- 2015-10-07 HK HK15109795.1A patent/HK1209049A1/xx not_active IP Right Cessation
-
2017
- 2017-01-27 NO NO20170133A patent/NO343244B1/no not_active IP Right Cessation
-
2018
- 2018-11-23 NO NO20181511A patent/NO344833B1/no not_active IP Right Cessation
Non-Patent Citations (2)
Title |
---|
ANDERSEN M.H. et al., Identification of a Cytotoxic T Lymphocyte Response to the Apoptosis Inhibitor Protein Survivin in Cancer Patients, Cancer Research, 2001, Vol. 61 (3), s. 869-872, Dated: 01.01.0001 * |
ANDERSEN M.H. et al., Spontaneous Cytotoxic T-Cell Responses against Survivin-derived MHC Class I-restricted T-Cell Epitopes in Situ As Well As ex Vivo in Cancer Patients, Cancer Research, 2001, Vol. 61 (16), s. 5964-5968, Dated: 01.01.0001 * |
Also Published As
Publication number | Publication date |
---|---|
NO20170133A1 (no) | 2004-08-02 |
ES2633389T3 (es) | 2017-09-21 |
JP2012211140A (ja) | 2012-11-01 |
ES2661082T3 (es) | 2018-03-27 |
HK1209050A1 (en) | 2016-03-24 |
JP2015134762A (ja) | 2015-07-27 |
CN103288920A (zh) | 2013-09-11 |
JP2012082213A (ja) | 2012-04-26 |
PT2359841E (pt) | 2015-02-10 |
NO344833B1 (no) | 2020-05-18 |
ES2529203T3 (es) | 2015-02-17 |
NO343244B1 (no) | 2018-12-17 |
HK1209049A1 (en) | 2016-03-24 |
JP5931585B2 (ja) | 2016-06-08 |
EP2857035B1 (en) | 2017-11-29 |
JP5509185B2 (ja) | 2014-06-04 |
EP2857035A1 (en) | 2015-04-08 |
HK1134030A1 (en) | 2010-04-16 |
JP6021961B2 (ja) | 2016-11-09 |
DK2359841T3 (en) | 2015-02-02 |
CN103288920B (zh) | 2015-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20053999L (no) | Survivin-avledede peptider og bruken av dem | |
ES2924709T3 (es) | Métodos de aislamiento de receptores de células T que tienen especificidad antigénica para una mutación específica de cáncer | |
CY1117387T1 (el) | ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ | |
DK1734049T3 (da) | Tumorassocierede peptider, der binder til MHC-molekyler | |
DE602006011030D1 (de) | Tumorassoziierte peptide, die promiskuitiv an humane leukozytenantigen- (hla-) moleküle der klasse ii binden | |
ATE512160T1 (de) | T-cell-epitope aus dem unreifen lamininrezeptorprotein (oncofoetal antigen) und deren medizinische verwendungen | |
NO20181511A1 (no) | Survivin-avledede peptider og bruken av dem | |
EP1071443A4 (en) | ISOLATED PEPTIDES CORRESPOND THE NY-ESO-1 AMINO ACID SEQUENCES AND BIND TO MHC CLASS I AND MHC CLASS II MOLECULES AND THEIR USE | |
EP1546188A4 (en) | P53 BINDING T-CELL RECEPTOR MOLECULES AND THEIR USES | |
EP2277918A3 (en) | Mhc class I and II peptide antigens derived from tumour antigen 5t4 | |
DK0996636T3 (da) | HA-1-antigenet | |
UY26170A1 (es) | Antigeno (c42) asociados a tumores | |
WO2002022803A3 (en) | Peptide epitopes recognized by antigen specific cd4+ t lymphocytes | |
NO20072457L (no) | Plasmider som koder for p185neu proteinsekvensvarianter og terapeutisk anvendelse derav | |
DK1444261T3 (da) | Immunogene ALK (anaplastisk lymfomakinase) peptider | |
SE9902989D0 (sv) | Novel compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |